drugset
drugset / Trial / NCT01891968

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

NCT01891968 ↗

Phase 2 Completed 15 enrolled M.D. Anderson Cancer Center Millennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if bortezomib can help to control MDS. The safety of this drug will also be studied. Bortezomib is designed to block a protein that causes cells to grow. This may cause cancer cells to die.

Timeline

Start
2013-08-07
Primary completion
2017-01-18
Completion
2017-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 1.3 mg/m2 Subcutaneous

Indications

leukemia